Fluciclovine F18 for Adenocarcinoma
This study is evaluating whether a PET/CT scan using fluciclovine F18 or 68Ga-PSMA may help plan radiation treatments and enhance outcomes in patients with prostate aden
See full descriptionAbout the trial for Adenocarcinoma
Treatment Groups
This trial involves 2 different treatments. Fluciclovine F18 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
About The Treatment
Eligibility
This trial is for male patients aged 18 and older. There are 6 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Fluciclovine F18 will improve 1 primary outcome and 6 secondary outcomes in patients with Adenocarcinoma. Measurement will happen over the course of Up to 5 years after study start.
Who is running the study
Principal InvestigatorPatient Q & A Section
Is fluciclovine f18 typically used in combination with any other treatments?
Fluciclovine H Cl has been used in combination with radiation, radical prostatectomy, and hormone therapy. Data from a recent study support the conclusion that the combination of radiation with fluciclovine H Cl would be highly effective in the treatment of prostate cancer.
Can adenocarcinoma be cured?
Adenocarcinoma can be cured only in a very rare case. It is impossible to cure it, but it can be controlled and it can be avoided in its early stages. Patients can be motivated not to develop it.
Does fluciclovine f18 improve quality of life for those with adenocarcinoma?
These data support the use of F18 in patients with locally advanced or metastatic adenocarcinoma. The small but significant increase in QOL that was seen in the treated group, relative to the control group, warrants further study.
How serious can adenocarcinoma be?
adenocarcinoma remains a very serious disease with a very poor post-operative prognosis. Despite the increased awareness and improved understanding of the disease, the use of surgery remains the gold standard treatment. The management of patients with adenocarcinoma remains problematic and it often requires referral to a tumor board outside the field of oncology.
What are common treatments for adenocarcinoma?
Treatment of adenocarcinoma varies widely, depending on many factors like surgeon experience and the availability of new treatments like definitive chemoradiotherapy and chemotherapy. Adjuvant chemotherapy is a common practice in the United States, while in the U.K. it is much less common. More than half of cancers will come down on untreated, untreated tumors.
What causes adenocarcinoma?
Adenocarcinoma involves both benign tumor-like processes as well as malignant cancerlike processes, and can be caused by any of several mechanisms. It is important to differentiate adenocarcinoma from adenoma as the two can usually be distinguished on endoscopic ultrasound imaging.
How many people get adenocarcinoma a year in the United States?
Adenocarcinoma is the second-most common cancer in American men. Each year, 1.5 million men are diagnosed with this disease. Over half (53%) of newly diagnosed cancers in the U.S. are metastatic, and 7 million people will die of the disease. Adenocarcinoma of the pancreas, colorectal, or stomach accounts for almost two-thirds (64%) of all new cases.
What is adenocarcinoma?
Adenocarcinoma is a malignant (cancerous) type of adenocarcinoma and is a form of adenocarcinoma of the colon. Adenocarcinomas are the most common form of colorectal cancer and are generally more aggressive than other types but most frequently metastatic to the lymph nodes. Symptoms of adenocarcinoma tend to occur earlier at an earlier age than other types of colorectal cancer. The development of metastatic adenocarcinoma depends to a large extent upon the stage of the disease. Metastatic adenocarcinoma may either be synchronous or metachronous.
What are the signs of adenocarcinoma?
Results from a recent clinical trial are useful when assessing breast masses, particularly in the setting of high-risk populations such as pre-menopausal women and African American women.
What are the latest developments in fluciclovine f18 for therapeutic use?
Data from a recent study confirm that fluciclovine is being effectively used as a therapeutic agent and it is a drug with a new application paradigm similar to that of flutamide for prostate cancer. Data from a recent study suggest that flucidline may be useful even in the therapeutic setting where we encounter patients with high levels of circulating testosterone.
What does fluciclovine f18 usually treat?
Fluciclovine was effective for most of our patients with elevated tracers. However, the majority (53%) of the patients needed to undergo one or more procedures. Results from a recent clinical trial indicate that fluciclovine for most of our patients does not allow the use of PET at the time of initiation of therapy.
How quickly does adenocarcinoma spread?
A significant number of patients with adenocarcinoma are known to have early metastasis. The most common time of metastasis development was 15 to 30 months after diagnosis; earlier time points were seen less frequently. Lymph node involvement was more common for carcinoma than for squamous cell carcinoma.